Alirocumab: Difference between revisions
Petrarchan47 (talk | contribs) →History: re-added cost/USA Today article per talk |
Undid revision 673059581 by Petrarchan47 (talk) please back off and hold your horses. i'll be done in an hour or two |
||
| Line 40: | Line 40: | ||
It was discovered by [[Regeneron Pharmaceuticals]] and is being co-developed with [[Sanofi]]. A main competitor in the race to worldwide health authority approval is [[evolocumab]] in development by Amgen.{{cn}} |
It was discovered by [[Regeneron Pharmaceuticals]] and is being co-developed with [[Sanofi]]. A main competitor in the race to worldwide health authority approval is [[evolocumab]] in development by Amgen.{{cn}} |
||
In July 2015, the FDA approved alirocumab to lower [[LDL cholesterol]] for people who have [[familial hypercholesterolemia|hereditary high cholesterol]] and people with [[atherosclerosis]] who require additional lowering of LDL cholesterol when diet and [[statin]] treatment have not worked.<ref name=FDA2014>FDA. July 24, 2015 [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455883.htm FDA Press release: FDA approves Praluent to treat certain patients with high cholesterol]</ref> This was the first approval of a [[PCSK9]] inhibitor.<ref name=FDA2014/ |
In July 2015, the FDA approved alirocumab to lower [[LDL cholesterol]] for people who have [[familial hypercholesterolemia|hereditary high cholesterol]] and people with [[atherosclerosis]] who require additional lowering of LDL cholesterol when diet and [[statin]] treatment have not worked.<ref name=FDA2014>FDA. July 24, 2015 [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455883.htm FDA Press release: FDA approves Praluent to treat certain patients with high cholesterol]</ref> This was the first approval of a [[PCSK9]] inhibitor.<ref name=FDA2014/> |
||
==Research== |
==Research== |
||
Revision as of 20:13, 25 July 2015
 | This article or section is in a state of significant expansion or restructuring. You are welcome to assist in its construction by editing it as well. If this article or section has not been edited in several days, please remove this template. If you are the editor who added this template and you are actively editing, please be sure to replace this template with {{in use}} during the active editing session. Click on the link for template parameters to use.
This article was last edited by Jytdog (talk | contribs) 8 years ago. (Update timer) |
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | Proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| Clinical data | |
| Trade names | Praluent |
| Routes of administration | Subcutaneous injection |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C6472H9996N1736O2032S42 |
| Molar mass | 146.0 kDa g·mol−1 |
Alirocumab (trade name Praluent)[1] is a human monoclonal antibody PCSK9 inhibitor biopharmaceutical drug approved by the FDA in July 2015 as a second line treatment of hypercholesterolemia for people whose cholesterol is not controlled by diet and statin treatment. It is also known as REGN727 and SAR236553.[2]
History
It was discovered by Regeneron Pharmaceuticals and is being co-developed with Sanofi. A main competitor in the race to worldwide health authority approval is evolocumab in development by Amgen.[citation needed]
In July 2015, the FDA approved alirocumab to lower LDL cholesterol for people who have hereditary high cholesterol and people with atherosclerosis who require additional lowering of LDL cholesterol when diet and statin treatment have not worked.[3] This was the first approval of a PCSK9 inhibitor.[3]
Research
A phase 3 trial of statin intolerant patients called ODYSSEY ran for 65 weeks.[4] Results were presented at the 2014 European Society of Cardiology meeting.[5]
A 78-week study of alirocumab in 2341 people taking statins who were at high risk for cardiovascular events and had high LDL cholesterol levels was published in April 2015.[6]
References
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization
- ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 24316621, please use {{cite journal}} with
|pmid=24316621instead. - ^ a b FDA. July 24, 2015 FDA Press release: FDA approves Praluent to treat certain patients with high cholesterol
- ^ "Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial". Journal of Clinical Lipidology. 8: 554–61. Nov–Dec 2014. doi:10.1016/j.jacl.2014.09.007. PMID 25499937.
- ^ "Huge Decreases in LDL Cholesterol With Alirocumab: ODYSSEY".
- ^ Robinson, Jennifer G.; Farnier, Michel; Krempf, Michel; Bergeron, Jean; Luc, Gérald; Averna, Maurizio; Stroes, Erik S.; Langslet, Gisle; Raal, Frederick J. (April 16, 2015). "Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events". New England Journal of Medicine. 372 (16): 1489–1499. doi:10.1056/NEJMoa1501031. ISSN 0028-4793. PMID 25773378.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |